Arena up on promise of gut pain drug

25 September 2018

San Diego, USA-based Arena Pharmaceuticals (Nasdaq: ARNA) has announced results showing both immediate and lasting reductions in pain in patients with Crohn's disease-associated chronic gut pain that were treated with olorinab.

In-pre market trading early on Tuesday, Arena’s share price was up by nearly 4%, perhaps a reflection of the strong clinical need for non-opiate treatments for the management of chronic abdominal pain in patients with gastrointestinal (GI) disorders.

Olorinab is a peripherally-restricted, fully-synthetic and highly-selective full agonist of the CB2 receptor being developed for the treatment of visceral pain associated with GI-disorders.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK